Last updated: 21 March 2023 at 7:30pm EST

Mark J. Holdbrook Net Worth




The estimated Net Worth of Mark J. Holdbrook is at least $106 Tisíc dollars as of 17 March 2023. Mark Holdbrook owns over 386 units of Tarsus Pharmaceuticals stock worth over $101,474 and over the last 4 years Mark sold TARS stock worth over $4,995.

Mark Holdbrook TARS stock SEC Form 4 insiders trading

Mark has made over 2 trades of the Tarsus Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Mark sold 386 units of TARS stock worth $4,995 on 17 March 2023.

The largest trade Mark's ever made was exercising 2,653 units of Tarsus Pharmaceuticals stock on 15 March 2023 worth over $84,365. On average, Mark trades about 760 units every 1 days since 2021. As of 17 March 2023 Mark still owns at least 3,191 units of Tarsus Pharmaceuticals stock.

You can see the complete history of Mark Holdbrook stock trades at the bottom of the page.



What's Mark Holdbrook's mailing address?

Mark's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.

Insiders trading at Tarsus Pharmaceuticals

Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over $38,362,333 worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth $16,525,269 . The most active insiders traders include Investments, Lpwong Roderic..., Capital Ix, Llc Vivo Capita... a William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $729,047. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth $912,800.



What does Tarsus Pharmaceuticals do?

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.



Complete history of Mark Holdbrook stock trades at Tarsus Pharmaceuticals

Osoba
Trans.
Transakce
Celková cena
Mark J. Holdbrook
V.P. a Clinical Affairs
Prodej $4,995
17 Mar 2023
Mark J. Holdbrook
V.P. a Clinical Affairs
Využití opce $36,452
15 Mar 2023


Tarsus Pharmaceuticals executives and stock owners

Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include: